May 2026

Contents

Journal scan

• New study predicts that PrEP efficacy in men is driven by drug levels in cells: matching earlier results in women

• Review of immune-based approaches to an HIV cure

• HIV rates in transgender people in Australia drops by 94% as PrEP access increases over 10 years

Early access

• Long-lived macrophages might explain non-suppressible low-level viraemia on ART

Special reports

• England’s HIV Action Plan: on target for HIV 2030 goals on preventable deaths but not for diagnoses: some key populations not included

Conference reports

• 6th BHIVA/BASHH Spring Conference 2026

• BHIVA 2026: HIV and neurodiversity includes higher concerns over adherence

• BHIVA 2026: Low engagement with sexual health clinics in NASTAL-4 survey

• BHIVA 2026: Limited drug resistance after doxyPEP in Liverpool: uptake of 4CMenB vaccine

• BHIVA 2026: Liverpool University launches new PrEP drug interaction website

• CROI 2026: Low levels of bNAbs detected in rectal tissue up to 46 weeks post infusion

• CROI 2026: Nine comprehensive free reviews in Topics in Antiviral Medicine

Antiretrovirals

• Paediatric dolutegravir/lamivudine submitted to EMA and FDA for use in younger children

Future meetings

• Future meetings and webinars 2026